Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Karen Brown

Forensic Psychiatry Houston, TX Medical Doctor

NPI 1558342956 CMS profile 343045

820 Gessner Rd, #750, Houston, TX 77024

Open in the dashboard

General payments

$17,392

791 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karen Brown of Houston, TX is reported in the CMS Open Payments database as having received $17,392 across 791 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Forensic Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,873 89
2024 General $1,708 75
2023 General $1,267 65
2022 General $1,785 99
2021 General $5,590 158
2020 General $2,805 162
2019 General $2,363 143

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karen Brown
  • Forensic Psychiatry median
  • Middle half of Forensic Psychiatry
  • National median

In program year 2025, general payments to Karen Brown were reported at $1,873. Among 86 Forensic Psychiatry profiles paid that year, the median was $125 and the middle half received between $34 and $306.

Show as a table
Year Karen Brown Forensic Psychiatry median Middle half National median
2019 $2,363 $143 $61–$431 $163
2020 $2,805 $112 $36–$301 $114
2021 $5,590 $113 $38–$343 $132
2022 $1,785 $113 $67–$475 $149
2023 $1,267 $139 $66–$415 $160
2024 $1,708 $117 $36–$341 $164
2025 $1,873 $125 $34–$306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $3,057 33 payments
  2. Otsuka America Pharmaceutical, Inc. $1,845 106 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,306 64 payments
  4. ITI, Inc. $1,275 60 payments
  5. AbbVie, Inc. $1,219 79 payments
  6. Vanda Pharmaceuticals Inc. $885 40 payments
  7. Bausch Health US, LLC $775 43 payments
  8. Teva Pharmaceuticals USA, Inc. $745 39 payments
  9. Sunovion Pharmaceuticals Inc. $637 40 payments
  10. Neurocrine Biosciences, Inc. $505 23 payments
  11. Other $5,143 264 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,868 780 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,340 1 payment
  3. Education $184 10 payments
Products named General payments · program years 2019–2025
  1. SPRAVATO $2,944 26 payments
  2. REXULTI $1,491 83 payments
  3. VYVANSE $1,011 48 payments
  4. CAPLYTA $995 47 payments
  5. VRAYLAR Neuroscience $973 65 payments
  6. HETLIOZ $748 34 payments
  7. APLENZIN $729 41 payments
  8. FANAPT $711 31 payments
  9. LATUDA $637 40 payments
  10. VRAYLAR Neuroscience $571 52 payments
  11. Other $10,438 527 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

3,872

Median for Neuropsychiatry: 88

Drug cost

$582,371

Median for Neuropsychiatry: $2,689

Branded share of claims

27.1%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 37 $301,647
Spravato Esketamine Hcl Brand 33 $55,142
Rexulti Brexpiprazole Brand 28 $52,980
Trintellix Vortioxetine Hydrobromide Brand 13 $18,990
Vyvanse Lisdexamfetamine Dimesylate Brand 46 $17,033
Cymbalta Duloxetine Hcl Brand 14 $14,643
Lurasidone Hcl Generic 59 $11,930
Fetzima Levomilnacipran Hcl Brand 14 $10,454
Lisdexamfetamine Dimesylate Generic 40 $10,123
Zubsolv Buprenorphine Hcl/Naloxone Hcl Brand 12 $8,638

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $267
$267 — —
VRAYLAR
  • AbbVie, Inc. $239
$239 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $225
$225 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $132
$132 28 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $105
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

791 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Forensic Psychiatry in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record